title: [Cytoflavin in the treatment of preschool and early school age children with the consequences of perinatal hypoxic brain damages].
abstract: OBJECTIVE
  To study the efficacy and safety of the complex metabolic neuroprotector cytoflavin in children with the consequences of perinatal hypoxic brain damages.
  
  
  METHODS
  Patients, aged 4-8 years, were stratified into three groups: 35 with infant cerebral palsy, 64 with the minimal brain dysfunction and 47 with sensorineural hearing loss. The control group consisted of 30 children. Monotherapy with cytoflavin was carried out in the dose of one tablet twice a day for 25 days. Neurologic status, neurophysiological examination andneuropsychophysiological testing were performed before and after treatment.
  
  
  CONCLUSIONS
  The efficacy of cytoflavin in children of preschool and early school agewas demonstrated. A complex neuroprotective action, including vasoactive, nootropic and antiasthenic effects, was revealed. Side-effects of cytoflavin were not observed.
authors.affiliation: Clinic of Nervous Diseases of Irkutsk State Medical University, Irkutsk, Russia.
authors.forename: S Yu
authors.initials: SY
authors.lastname: Lavrick
authors.affiliation: Irkutsk State Medical Academy of Continuing Education, Irkutsk, Russia.
authors.forename: V V
authors.initials: VV
authors.lastname: Shprakh
authors.affiliation: Clinic of Nervous Diseases of Irkutsk State Medical University, Irkutsk, Russia.
authors.forename: S V
authors.initials: SV
authors.lastname: Domitrak
authors.affiliation: Clinic of Nervous Diseases of Irkutsk State Medical University, Irkutsk, Russia.
authors.forename: A S
authors.initials: AS
authors.lastname: Borisov
mesh_terms: D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy* / Q000209:etiology; D001930:Brain Injuries / Q000188:drug therapy* / Q000209:etiology; D002547:Cerebral Palsy / Q000188:drug therapy* / Q000209:etiology; D002648:Child; D004338:Drug Combinations; D005260:Female; D005486:Flavin Mononucleotide / Q000627:therapeutic use*; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D002534:Hypoxia, Brain / Q000150:complications*; D007290:Inosine Diphosphate / Q000627:therapeutic use*; D009536:Niacinamide / Q000627:therapeutic use*; D018697:Nootropic Agents; D036801:Parturition; D011247:Pregnancy; D013386:Succinates / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D018697:Nootropic Agents; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate